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Abstract
Islet amyloid polypeptide (IAPP, amylin) is secreted from pancreatic islet L-cells and converted to amyloid deposits in type
2 diabetes. Conversion from soluble monomer, IAPP 1^37, to L-sheet fibrils involves changes in the molecular conformation,
cellular biochemistry and diabetes-related factors. In addition to the recognised amyloidogenic region, human IAPP (hIAPP)
20^29, the peptides human or rat IAPP 30^37 and 8^20, assume L-conformation and form fibrils. These three amyloidogenic
regions of hIAPP can be modelled as a folding intermediate with an intramolecular L-sheet. A hypothesis is proposed for co-
secretion of proIAPP with proinsulin in diabetes and formation of a ‘nidus’ adjacent to islet capillaries for subsequent
accumulation of secreted IAPP to form the deposit. Although intracellular fibrils have been identified in experimental
systems, extracellular deposition predominates in animal models and man. Extensive fibril accumulations replace islet cells.
The molecular species of IAPP that is cytotoxic remains controversial. However, since fibrils form invaginations in cell
membranes, small non-toxic IAPP fibrillar or amorphous accumulations could affect L-cell stimulus-secretion coupling. The
level of production of hIAPP is important but not a primary factor in islet amyloidosis ; there is little evidence for
inappropriate IAPP hypersecretion in type 2 diabetes and amyloid formation is generated in transgenic mice overexpressing
the gene for human IAPP only against a background of obesity. Animal models of islet amyloidosis suggest that diabetes is
induced by the deposits whereas in man, fibril formation appears to result from diabetes-associated islet dysfunction. Islet
secretory failure results from progressive amyloidosis which provides a target for new therapeutic interventions. ß 2001
Elsevier Science B.V. All rights reserved.
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1. Introduction
The ¢rst description of amyloid deposits in pan-
creatic islets of a diabetic subject were made more
than 100 years ago [1]. This is one of the most com-
mon pathological features of diabetes, which a¡ects
more than 150 million individuals worldwide [2]. The
causal factors for the many pathophysiological fac-
tors that contribute to type 2 diabetes are largely
unknown; these include both the relationship of islet
amyloid to the disease processes in diabetes as well as
the causative factors for conversion of the compo-
nent peptide to insoluble ¢brils. Improved under-
standing of pancreatic islet function in diabetes and
development of biophysical methods to investigate
protein folding processes have resulted in new ap-
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proaches to the problem of how amyloid forms and
how it a¡ects islet function.
Islet amyloid ¢brils are formed from islet amyloid
polypeptide (IAPP), also known as ‘amylin’, which is
a 37 amino acid peptide co-secreted with insulin from
the L-cells of pancreatic islets in both diabetic and
non-a¡ected subjects [3^6]. Under normal circum-
stances, IAPP is released into the circulation and is
Fig. 1. Pancreatic islet structure in non-diabetic and type 2 diabetic subjects. (a) Islet of a non-diabetic subject immunolabelled for in-
sulin (brown); insulin-containing L-cells occupy more than 80% of the islet space. (b) Islet of a diabetic subject labelled for insulin
(brown) and stained with congo red for amyloid (pink); more than 50% of the islet space is ¢lled with congo red stained, amorphous
amyloid deposit (asterisk). The remaining L-cells are localised at the edges of the deposits. (a,b) Scale bar = 20 Wm.
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excreted via the kidney [7,8]. The molecular mecha-
nisms that result in refolding of the peptide to con-
vert it from a normally soluble monomer into insolu-
ble ¢brils have not been identi¢ed. Amyloid ¢brils
are formed from misfolded IAPP and are deposited
in pancreatic islets adjacent to the islet cells (Fig. 1);
islet amyloidosis can a¡ect less than 1% or up to 80%
of islets in a diabetic individual [9^12]. This localised
pancreatic amyloid deposition di¡ers from systemic
amyloidoses where the ¢brils are formed from other
peptides including serum amyloid A and IgGs, and
are deposited in many organs. The occurrence of islet
amyloid in non-diabetic subjects is low, less than
15% in elderly, apparently non-diabetic individuals,
but is high in more than 90% of diabetic subjects at
post-mortem [4,10,13]. Although small changes in the
amino acid sequence of IAPP play a role in the spe-
cies speci¢city of diabetes-associated amyloid forma-
tion, there is no evidence for production of a mu-
tated form of IAPP in the majority of diabetic
patients [14,15]. This suggests that disease-associated
changes in the islet and in production of IAPP play a
role in ¢brillogenesis in diabetes.
The relationship between the complex pathophysi-
ology of the diabetic syndrome in man and islet amy-
loid formation remains unclear; severe islet amy-
loidosis is correlated with the need for insulin
replacement therapy and loss of islet L-cells
[10,12,13]. Experiments in vitro have demonstrated
that synthetic amyloid ¢brils are cytotoxic [16^19].
Similar cytotoxic e¡ects have been seen with ¢brils
formed from synthetic AL (the Alzheimer’s disease
amyloid peptide) [19^21]. The mechanism of ¢bril-
induced toxicity in Alzheimer’s disease (AD) and dia-
betes involves interaction between the cell membrane
and misfolded proteins but the toxic form of the
protein has yet to be determined.
This review discusses the process of amyloid for-
mation from the misfolding of the IAPP molecule to
the e¡ects of ¢bril formation on organ function in
diabetes in animal models and man. Following a
brief description of some of the relevant aspects of
the pathophysiology of type 2 diabetes, the structure
of the IAPP molecule is discussed in relation to mo-
lecular events that could occur in the refolding of
IAPP and its conversion to ¢brils. The potential
changes in the biochemistry of islet function in dia-
betes are related to misfolding of IAPP. The feed-
back of amyloid on biochemical processes and islet
secretion is examined. Animal models of IAPP amy-
loidosis including transgenic mice expressing the hu-
man IAPP gene are discussed in relation to the
course of the diabetic syndrome in man. A diagram-
matic plan of how these processes interact is pre-
sented to highlight the relationship between islet
function and misfolding of human IAPP (hIAPP)
in type 2 diabetes.
2. Type 2 (non-insulin-dependent) diabetes and
amyloid
There are two major types of diabetes in man,
both of which result in a disturbance of the normally
tight control of glucose homeostasis e¡ected by in-
sulin secreted from pancreatic islets. Type 1 (insulin-
dependent) diabetes develops in individuals mostly
under the age of 30 years and is an autoimmune
disease resulting in destruction of insulin-secreting
cells and the requirement for insulin replacement
therapy. Type 2 diabetes develops in individuals
mostly over the age of 40 years [22] and is a multi-
factorial disease with genetic and environmental
components; it is characterised by a progressive de-
terioration in the regulation of blood glucose concen-
trations usually associated with obesity, decreased
physical activity and increased calorie intake. Re-
cently the incidence of type 2 diabetes has increased
in both younger individuals as well as in the older
age group; the increase of a¡ected individuals under
the age of 20 is attributed to similar factors [23].
Amyloid is formed only in type 2 diabetic subjects
since destruction of the islet L-cells in type 1 diabetes
removes the source of IAPP. Therefore, this review is
restricted to features of type 2 diabetes.
Type 2 diabetes is characterised by a disruption of
the secretion of insulin from islet L-cells and de-
creased insulin sensitivity of peripheral tissues (in-
creased insulin resistance) [24^26]. These two patho-
physiological features are present to varying degrees
in di¡erent patients. Increased circulating insulin
concentrations are a marker for the decreased insulin
sensitivity occurring in obesity whereas L-cell dys-
function results in lack of appropriate insulin secre-
tion in relation to the ambient glucose concentra-
tions. At diagnosis, many patients can be treated
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with dietary advice. If this is ine¡ective, insulin se-
cretion can be augmented by sulphonylurea drugs,
which stimulate L-cell secretion. When this fails dur-
ing the progression of the disease, insulin replace-
ment therapy in the form of injections is required.
This usually marks the ¢nal stages of the syndrome
when endogenous insulin secretion is severely com-
promised. Although amyloid deposition is a recog-
nised feature of the islets in type 2 diabetic subjects
at post-mortem, it is unclear if the deposits are a
causal factor for any aspect of the disease, or develop
as a result of the disease, and whether they a¡ect the
progressive deterioration of insulin secretion and by
what mechanism.
The highest prevalence of type 2 diabetes is found
in indigenous populations that have become ‘Wester-
nised’. These include the Pima Indians of Arizona
[27] where the prevalence is greater than 50% in
age groups over 35 years and amyloid is present in
diabetic subjects [28], the Australian aboriginal peo-
ples [29] and the Nauruans of the Paci¢c Islands [30].
Type 2 diabetes has a familial association but
although many candidate genes have been proposed,
clear associations with mutant genes have been iden-
ti¢ed in only a small percentage of individuals af-
fected by the disease [31].
3. What molecular features of IAPP are involved in
transition from monomer to ¢bril?
3.1. Amyloidogenic regions of the IAPP molecule
Observations of the process of folding of human
IAPP and amyloid ¢bril formation in vitro have been
complicated by the fact that most synthetic IAPP
preparations contain ¢brils before investigations
commence, making it very di⁄cult to de¢ne a soluble
‘native state’ of this peptide. Furthermore, in vitro
observations are confounded by di¡erences in the
method of peptide preparation, pH of the experi-
ments, the use of concentrated stock solutions which
may contain ¢brils and the vast range of concentra-
tions and solvents used in di¡erent laboratories. In
the presence of helix-inducing organic solvents, such
as 2,2,2-tri£uoroethanol (TFE) or 1,1,1,3,3,3-hexa-
£uoro-2-propanol (HFIP), the circular dichroic
(CD) spectrum of hIAPP suggests an K-helical struc-
ture [32,33]. These solvents, together with DMSO,
have been used extensively to examine the conforma-
tion of IAPP and the amyloidogenic AL peptide
[34,35] but do not permit extrapolation to in vivo
conditions where the three-dimensional structure
will be di¡erent. Recent careful studies of puri¢ed
peptide have shown that a ‘native state’ of human
IAPP can be predicted; in the absence of organic
solvents and with the elimination of potential ‘seeds’
by ¢ltration, the CD spectra of hIAPP solubilised in
water remained stable for many days. The peptide
exhibited a random coil structure suggesting an un-
folded state in aqueous medium [36,37]. However,
the state in which hIAPP is found in the cell and
circulation is still unknown.
IAPP is expressed in pancreatic islets of all mam-
malian species so far examined but the potential to
form amyloid is related to species-speci¢c di¡erences
in the amino acid sequence (Fig. 2). Diabetes-associ-
ated amyloid is found in primates [38,39] and cats
[40,41] but not in rodents. This has been attributed
to alterations in the amino acid sequence in the re-
gion IAPP 20^29 [42,43]: proline substitutions in this
region in rodents and some other species are thought
to be the major factors preventing refolding of the
molecule into L-conformation and assembly into typ-
ical amyloid ¢brils [43,44].
Until recently, the single amyloidogenic region,
spanning residues 20^29, had been proposed to be
involved in ¢bril formation of hIAPP, [43,45^47].
This L-strand peptide fragment has been used to
model the formation of intermolecular interactions
and L-sheet formation of oligomers of hIAPP and
was considered to be the only L-sheet region of the
peptide. However, recent studies have identi¢ed a
second amyloidogenic region, hIAPP 30^37, which
forms amyloid-like ¢brils in aqueous medium [48].
In addition, a peptide fragment of IAPP consisting
of residues 8^20 has been shown to form ¢brils [49].
These two additional regions of potential L-confor-
mation have important consequences for folding not
only of human but also of rodent IAPP and of IAPP
in all other species where the sequence is largely con-
served. The region IAPP 8^20 of rodent IAPP con-
tains a single amino acid substitution, His18Arg (Fig.
2), which has been shown to have no a¡ect on for-
mation of ¢brils from rat IAPP 8^20. This lack of
e¡ect of histidine as a major determinant of ¢bril
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formation is in contrast to the important role of His
in ¢bril formation from the amyloidogenic peptide
AL [50]. At the C-terminus of the molecule, rat
IAPP 30^37 and hIAPP 30^37 are completely homol-
ogous and form ¢brils. Thus, in the rodent molecule,
two potentially amyloidogenic domains exist [49] but
are separated by the proline rich domain, 20^29,
which prevents L-sheet formation. These recently ac-
quired data indicate that there are three molecular
domains of the human IAPP sequence which could
have a role in the assembly of L-sheets, namely ami-
no acid regions 8^20, 20^29, and 30^37. With the
presence of more than one potential L-strand region,
interactions within a monomer as well as between mol-
ecules could occur during L-sheet formation. There-
fore, the folding processes involved in ¢bril forma-
tion via the creation of unfolded intermediates, as
has been proposed for other amyloidogenic proteins
[51,52], are likely to be more complex than those
envisaged for molecular association via a single
strand involving only the region IAPP 20^29 [47].
3.2. Modelling hIAPP folding Intermediates
The intermediate molecular forms of hIAPP cre-
ated during ¢brillogenesis can be modelled in vari-
ous conformations dependent upon the number of
L-sheet components present in a native monomer
or folding intermediate. A L-turn has been predicted
at asparagine 31 [36], which would result in two ad-
jacent L-strands, hIAPP 32^37 and 24^29, creating
an antiparallel L-sheet. The third L-strand contained
in the fragment 8^20 could extend this sheet with a
turn in the region 18^23 (predicted at serine 20) [36].
A computer model incorporating three strands, 8^20,
20^29 and 30^37, with two turns predicts a structure
which could form an intramolecular L-sheet (Fig.
3a). The ¢rst turn between amino acids 17 and 19
is depicted as a loop rather than a tight turn. Resi-
dues Asp22, Gly24, Ile26, Leu27 and Ser28 have
been shown to be important for ¢bril formation
from proline substitution experiments [43,44]. These
residues would lie in the second strand region and be
localised on the outer edge of the L-sheet where they
would be involved in interactions between molecules
or proto¢laments necessary for assembly of two or
more proto¢laments into ¢brils. The L-sheet would
be disrupted in rat IAPP by the proline substitutions
in the region 24^27, which would prevent both intra-
and intermolecular H-bonding. Residue 28 is in the
second turn and a proline at 28 a¡ects the folding
and conversion to ¢brils as has been demonstrated
by substitution experiments [43,44]. The mutation
Ser20Gly, found in small numbers of Japanese type
2 diabetic subjects [53,54], is thought to accelerate
formation of ¢brils from hIAPP in vitro [55]; in
the proposed model, the S20G substitution would
result in a tighter angle on the loop due to the small-
er size of glycine. However, the mutation is relatively
uncommon in type 2 diabetes [56] and not all indi-
viduals with this mutation develop severe insulin-re-
quiring diabetes which would be associated with ex-
tensive amyloid deposition [54]. It is, therefore,
di⁄cult to reconcile the biophysical data with dia-
betic pathophysiology.
It is unlikely that the disulphide bridge between
residues 2 and 7 would allow the N-terminal portion
of hIAPP to adopt a L-sheet conformation: in the
              
  
Fig. 2. ProIAPP amino acid sequences in di¡erent species indicated by single letter code. Three residues are missing (:) in human,
monkey, cat and dog when aligned with other sequences. Porcine IAPP is missing one amino acid. Amino acids identical to those in
human proIAPP are indicated by a dash (^). Asterisks (*) represent amino acids not yet determined. Proline residues are present in
the region IAPP 20^29 in rat and mouse IAPP which prevent folding to form ¢brils. G-pig, guinea pig.
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Fig. 3. Models of human IAPP folding intermediates and assemblies. (a) A hypothetical model of a folded L-sheet monomer of hIAPP
represented in a space ¢lling diagram. (b) Linear diagram of the model. In (b) regions of L-strand are shown in yellow, turns are
shown in blue. Hydrogen bonds are shown with dotted lines. Hydrophobic residues (green stars) are involved in hydrogen bonding be-
tween the backbones of the L-strands. Serine 20, which is substituted with a glycine in a small subset of type 2 diabetic subjects, is labelled
with an asterisk. The model was generated using Insight II. (c) Possible conformation of stacked hIAPP molecules within a proto¢la-
ment. (i) Parallel stacking of molecules with parallel and antiparallel L-strands. (ii) Antiparallel stacking of peptide molecules with par-
allel interaction between molecules. L-Strands are shown in yellow and turns in blue. Direction of L-strands is marked with arrows.
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model, the N-terminal region, including the intact
cysteine bridge, would most likely lie outside the
boundaries of the L-sheet in a similar way to that
predicted for non-L-sheet regions of larger amyloid-
ogenic proteins [51,52]. The disulphide bridge is con-
served in all species and is believed to be necessary
for e¡ective biological activity of IAPP [57]. How-
ever, it is unclear if this bridge is intact in the mo-
lecular species that forms amyloid deposits since syn-
thetic IAPP without the bridge forms ¢brils in vitro.
IAPP ¢bril formation was found to be indepen-
dent of pH in the physiological range (5.5^7.4) [49]
and therefore it is unlikely that the charge on histi-
dine 18 is a major determining factor for ¢bril as-
sembly. During ¢bril growth, and as the proto¢la-
ment extends in length, intermolecular interactions
would occur due to the addition of monomers, pro-
to¢brils or small oligomers. Parallel and antiparallel
orientations of peptide monomers are possible in this
model (Fig. 3b). A parallel arrangement of molecules
would result in antiparallel intermolecular interac-
tions. An antiparallel arrangement of monomers re-
sults in parallel intermolecular L-strands. Determin-
ing the orientation of molecules by identi¢cation of
residues or charges exposed on the surface of the
native and synthetic proto¢laments will indicate
how the proto¢lament is assembled and provide clues
for the hIAPP misfolding process.
3.3. Fibril assembly from proto¢laments
The folding characteristics of the proposed model
would determine the width of the proto¢bril and
proto¢lament. The width of the IAPP molecule (the
strand between residues 17 and 28 in the model) (Fig.
3a) would be predicted to be V3 nm. A single
L-sheet monomer aligned perpendicular to the proto-
¢lament axis would result in a width of proto¢bril/
proto¢lament of 3^4 nm which is consistent with the
5 nm measured diameter of synthetic IAPP proto¢-
brils and proto¢laments observed by atomic force
microscopy (AFM) and electron microscopy (EM)
(Fig. 4a). Proto¢laments formed from the similarly
sized AL 1^40 and from IAPP 25^35 have been
shown to have a width of V3 nm [58]. Fibril for-
mation incorporating between three and six proto¢-
laments of IAPP would therefore result in a ¢bril
diameter of 9^18 nm which agrees with measured
diameters of ¢brils formed from synthetic hIAPP in
vitro and from biosynthetic hIAPP in islets in vivo
and in vitro (Fig. 4b) [59]. Fibrils formed from hI-
APP 8^37 have been shown to di¡er from ¢brils
formed from full length IAPP 1^37 in that they ap-
pear to be composed of two rather than three pro-
to¢laments [59]. Therefore, rather than participating
in the actual ¢bril the N-terminal region may be a
modulating in£uence on the interactions between
proto¢laments.
Assembly of the proto¢laments into ¢brils is likely
to be dependent upon interaction of side groups ex-
posed on the surface of the proto¢lament. As an
example, histidine residues are involved in AL amy-
loid ¢bril assembly a¡ecting lateral association of
proto¢laments [50,60] possibly via the protonation
state of AL His13 which is a binding site for zinc
[61^64]. Although a role of zinc in IAPP ¢bril for-
mation is attractive since zinc concentration is high
in the L-cell secretory granule [65], the absence of
His18 in rat IAPP does not a¡ect ¢bril formation
from rat 8^20. It is more likely that assembly of
proto¢laments into ¢brils is dependent upon many
di¡erent features of the environment (salt and ionic
concentrations), extracellular proteins, the concentra-
tion of IAPP and interactions with other factors such
as heparan sulphate proteoglycans (HSPG). Obser-
vations on ex vivo IAPP ¢brils extracted from a pan-
creas of a diabetic patient (Fig. 4c) suggest that ¢-
brils formed in vivo in diabetes in man are relatively
uniform in morphology, approx. 10 nm wide, short,
straight and without the twisted and ribbon-like as-
semblies seen with synthetic IAPP ¢brils (Fig. 4a).
Experimental conditions that simulate the in vivo
situation would be more appropriate to determine
how ¢brils are assembled.
4. What features of the diabetic islet environment
could a¡ect IAPP peptide misfolding?
4.1. ProIAPP and aberrant proteolytic processing in
diabetes
Very little is understood about the cause of defec-
tive insulin secretion in type 2 diabetes despite con-
siderable laboratory and clinical investigations into
the e¡ects of elevated glucose (glucose toxicity), lip-
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ids (lipotoxicity) and potential genetic defects in the
machinery of stimulus-secretion coupling in the islet
L-cell (reviewed in [25]). However, some speci¢c bio-
chemical abnormalities have been identi¢ed and are
used as markers of abnormal islet activity in diabetic
patients. Increased secretion of the precursor of in-
sulin, proinsulin, together with intermediates of
proinsulin proteolysis indicate L-cell dysfunction
[66,67]. Proinsulin and proIAPP are processed by
the same prohormone convertase enzymes, PC1 and
PC2, and by carboxypeptidase E during their passage
through the Golgi and are packaged into maturing
secretory granules [68^70]. Therefore, proIAPP pro-
cessing could be a¡ected by the same unknown L-cell
pathology which a¡ects proinsulin proteolysis; there
would therefore be concurrent hypersecretion of pre-
cursors of both insulin and IAPP in diabetes. In
support of this hypothesis, mice lacking the gene
for PC2 secrete incompletely processed proIAPP
[71] and proinsulin and proIAPP processing inter-
mediates have been identi¢ed in extracts of human
islets in culture [72].
ProIAPP has been shown to have amyloidogenic
characteristics when examined both as a recombinant
and synthetic peptide [73,74]. The process of ¢bril
formation from this peptide appears to be less ag-
gressive than that observed for IAPP 1^37 [73]. How-
ever, if proIAPP were a causal factor for islet amy-
loid deposition, proIAPP or processing intermediates
would be expected to be present as components of
the deposits. Extraction studies indicated that IAPP
amyloid in both insulinomas and pancreatic material
of diabetic subjects and cats was formed from IAPP
1^37 and not a larger peptide [3,4]. However, if the
process of ¢bril assembly is initiated by a ‘seeding’
process [75], secretion and aggregation of incom-
pletely processed proIAPP fragments could act as
the ‘seed’ or ‘nidus’ for subsequent deposition of
IAPP. In diabetes, the most frequently secreted pro-
cessing intermediate of proinsulin is des 31,32 proin-
sulin, resulting from incomplete cleavage by PC2 at
the C-peptide/A chain junction of proinsulin [66,70].
Mice lacking the gene for PC2 have elevated levels of
the N-terminal intact proIAPP intermediate [71] and
the N-terminal processing intermediate has been
identi¢ed in extracts of human islets cultured in ele-
vated glucose concentrations [72]. It would be ex-
pected, therefore, that this fragment with the N-ter-
minus intact would be the processing fragment,
which, together with intact proIAPP, might be asso-
ciated with hyperproinsulinaemia of diabetes. This
fragment might therefore be localised in some amy-
loid deposits. Immunoreactivity for the N-terminal
region of proIAPP has been identi¢ed in some amy-
loid deposits [76,77] supporting this hypothesis.
Recent studies on proIAPP fragments have shown
that a binding site for heparan sulphate spans the
N-terminal cleavage site of proIAPP [78]. If proIAPP
is incompletely cleaved at the N-terminal site, it
would be secreted from the cell in this form. In the
extracellular islet space this intermediate could bind
to HSPG on the basement membrane. HSPG, to-
gether with other proteoglycans, has been proposed
as a co-factor for ¢bril assembly [79^81]. These ob-
servations taken together suggest that increased se-
cretion of proIAPP processing intermediates in dia-
betes could accumulate adjacent to the islet capillary
and form the ‘nucleus’ or ‘seed’ for misfolding and
assembly of secreted hIAPP. This would result in
initiation of ¢brillogenesis close to the capillary bor-
der, which is where many very small deposits are
located in vivo. This hypothesis requires develop-
ment of assay methods to determine if proIAPP
and processing intermediates are co-secreted with
proinsulin in diabetes and to determine if HSPG is
a co-factor for accumulation. Binding studies with
synthetic peptides and model building to determine
if HSPG will interfere with subsequent proto¢lament
assembly of IAPP would be required to con¢rm this
suggestion.
4.2. Glycation and islet amyloid in diabetes
Increased glycation of proteins is characteristic of
the hyperglycaemia of diabetes resulting in increased
fragility of red cell membranes, increased glycated
haemoglobin, and tissue damage as a result of for-
mation of advanced glycation end products (AGE)
[82]. IAPP glycation has been proposed as an impor-
tant factor in generation of ¢brils in diabetes [83].
However, IAPP amyloid is deposited also in human,
feline and canine insulinomas when glucose concen-
trations are low and glycation is minimal; this indi-
cates that formation of AGE products are not essen-
tial for IAPP ¢brillogenesis. AGE conversion is
associated with proteins with a long half-life such
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as collagen and haemoglobin. Monomeric secreted
IAPP has a half-life comparable with C-peptide of
30^40 min [7,84]. Therefore, glycation of the mono-
meric peptide is unlikely. However, once IAPP is
deposited as amyloid, the ¢brils would be targets
for glycation and sites for AGE conversion in hyper-
glycaemia of diabetes.
4.3. Additional components of islet amyloid and
diabetes
Amyloid deposits contain many components in ad-
dition to the protein ¢brils. Serum amyloid P com-
ponent (SAP) is found in all amyloid deposits includ-
ing islet amyloid [85] and has been proposed to
protect amyloid from degradation rather than pro-
mote ¢brillogenesis [86]. Acute induction of splenic
AA amyloidosis in SAP de¢cient mice has been
shown to be retarded and the amyloid cleared more
e¡ectively after the induction compared to that seen
in normal mice; this suggests that SAP has a role in
shielding amyloid from degradation [86]. SAP bind-
ing to amyloid deposits is calcium dependent and the
pancreas is high in calcium which accumulates as
insoluble aggregates both in pancreatic ducts in pan-
creatitis and in amyloid deposits [87]. Thus, SAP
could have an important role in protecting pancreatic
islet deposits from removal and degradation.
Apolipoprotein (Apo) E is also a component of
the deposits [88] and has been identi¢ed in islet cells
[89]. The commonly occurring isoform, ApoE O4 has
been implicated in plaque formation in AD [90].
ApoE has an important role in disorders of lipid
Fig. 4. Fibrils formed from synthetic and biosynthetic human
IAPP. (a) Synthetic hIAPP visualised with EM following nega-
tive staining with uranyl acetate. Fibrils in the form of twisted
proto¢laments (arrow) and ribbons were formed when synthetic
human IAPP was solubilised in sodium acetate. Scale bar = 200
nm. (b) Fibrils formed in vivo in the pancreas of a diabetic pa-
tient. The ¢bril-containing extract was visualised with platinum
carbon shadowing and EM. The ¢brils were relatively short
and uniform in width (approx. 6 nm) and morphology; there
was no evidence of complex twisting or sheet formation. Scale
bar = 200 nm. (c) Electron micrograph of amyloid ¢brils in an
islet section of a diabetic monkey examined with EM; ¢brils
which were relatively straight and not in the form of sheets
were immunolabelled for IAPP with 10 nm gold. Scale
bar = 200 nm.
6
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Fig. 5. Perivascular and extracellular amyloid in islets of (a) human, (b) primate and (c) hIAPP transgenic mouse. (a) Small amyloid accumulation (arrows) adjacent to
basement membrane (bm) in islet from a diabetic subject. This accumulation, which may not be ¢brillar, was immunogold labelled for IAPP (arrows) and would be
too small to be visualised by light microscopy. (b) Perivascular amyloid deposits were immunogold labelled for IAPP in an islet from a non-diabetic monkey; the amy-
loid ¢brils (asterisk) were located between the islet cells and the capillaries. (c) Extracellular IAPP ¢brils deposited between cells of an islet isolated from a mouse ex-
pressing human IAPP and cultured in 11.1 mM glucose for 6 days. Fibrils (asterisk) form between the cells and adjacent to the plasma membrane of the L-cells (ar-
rows). B, L-cell ; A, alpha cell ; C, capillary. Scale bars: (a) 1 Wm; (b) 5 Wm; (c) 5 Wm.
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metabolism [91] which are frequently associated with
type 2 diabetes. However, no association has been
found between ApoE genotype and the degree of
islet amyloidosis in post-mortem specimens or with
severity of diabetes [92]. Furthermore, islet amyloid
is deposited in ApoE de¢cient hIAPP transgenic mice
(S. Kahn, personal communication).
5. Where is the process of ¢brillogenesis initiated?
5.1. Fibril formation at extracellular sites
Spontaneously developing islet amyloid deposits
associated with diabetes in man, monkeys and cats
are almost exclusively at extracellular sites and, in
diabetic animals, are clearly visible with the light
microscope within the islet envelope [9,11,39,93^95].
However, much smaller deposits adjacent to islet
capillaries can be identi¢ed only with electron mi-
croscopy (Fig. 5a), suggesting that sub-pathological
deposits may be present early in the disease adjacent
to capillaries; as these deposits expand there could
be an impact on islet function. Such pericapillary
deposits are visible in islets of non-diabetic monkeys
(Fig. 5b); this amorphous mass could a¡ect nutrient
signalling and transfer of secretion between the islet
space and capillary. As the deposit expands due to
progressive IAPP deposition, the ¢bril mass extends
into the islet space, occupying areas that were previ-
Table 1
Concentrations of IAPP in di¡erent species in relation to islet amyloid formation
Species ND/D m/f Age (years) Rx IAPP (pmol/l) Insulin (pmol/l) Amyloid Ref.
Man ND s 40 none 7 (5.5^17) 65 (30^72) n/a [136]
D s 40 diet 12.5 (3^16.5) 85 (52^132) n/a
D s 40 sulph 6 (1.5^35) 107 (38^226) n/a
D s 40 insulin 3 (0.5^5.5) ^ n/a
Cat ND s 2 ^ 3.1 50 0 [105]
D Dex+GH s 2 sulph 9.8 ^ Y 4/4
D Dex+GH s 2 insulin 2.9 ^ Y 1/4
Monkey ND 6 10 none ^ 187 (201^431) 0 [39]
ND s 10 none ^ 250 (101^618) Y 2/9
ND obese s 10 none ^ 1206 (847^2230) Y 4/6
D s 10 none ^ 160 (65^345) Y 8/8
Age (weeks)
hIAPP T mice ND 82 ^ 157 38 N [101]
ND 32 ^ (63^38) (36^183) N [126]
ND 24 ^ 15 36 N [127]
ND ^ ^ 333 205 N [133]
D m/f 4 wk Rx Dex+GH 1135 595 Y 8/30
D m 32 fat diet n/a 360 Y 10/32 [130]
ND f 32 fat diet n/a 150 N
D m 16^20 homozy 85 70 Y [96]
ND f 16^20 homozy 130 220 N
D m 52 hIAPPUY 51 213 Y 8/8 [97]
D m 70 hIAPPUob 600 7255 Y 5/6 [99]
Data published from non-diabetic (ND) and diabetic (D) human and animal studies are related to the treatment (Rx) by sulphonylur-
ea (sulph), diet or insulin. Diabetes/amyloid deposition was induced in animal models by administration of dexamethasone (Dex) and
growth hormone (GH), by a high fat diet, by cross-breeding to produce mice expressing hIAPP in a ‘homozygous’ condition (homo-
zyg), or breeding against a background of obesity with the Agouti viable yellow mutation (Y) or the ob/ob strain (ob). Fasting con-
centrations of plasma IAPP and insulin are expressed in pmol/l and the occurrence of amyloid as detected by light microscopy (yes
(Y) or no (N)) in di¡erent sized cohorts of animals is presented where assessed (not assessed, n/a). There is no clear association of the
occurrence of amyloid with the circulating concentration of IAPP. The occurrence of amyloid in genetically determined obese hIAPP
transgenic mice (8/8, 5/6) is similar to that found in man (s 90%) but other mouse models show a much lower incidence of amyloid
deposition (8/30, 10/32).
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ously ¢lled with endocrine cells. Progressive amyloid
deposition is therefore associated with destruction/
replacement of islet cells in both man and animal
models [39,96,97].
Islet amyloid formation in experimental animal
and cellular models is largely associated with in-
creased production of hIAPP [96,98^100] (Table 1).
If increased secretion/decreased clearance of IAPP is
a causal factor for ¢bril formation, accumulation
would be expected to occur at extracellular sites
within the islet domain, on the di¡usion path be-
tween the cells and the capillaries (as shown in Fig.
5b). L-Cell secretagogues have been shown to in-
crease extracellular ¢bril formation in isolated cul-
tured hIAPP transgenic mouse islet preparations
[100,101]; in this experimental model where the capil-
laries are no longer functional, ¢brils formed be-
tween the islet cells (Fig. 5c) and the extent of extra-
cellular ¢bril accumulation was proportional to the
secretion of insulin and IAPP and independent of
whether the stimulus was glucose or an amino acid.
This indicates that increased secretion/decreased
clearance from the islet were important factors for
¢bril formation. The extent of intracellular ¢bril ac-
cumulation in these transgenic mouse islets was min-
imal and little cell death was observed concluding
that biosynthetic hIAPP forms extracellular ¢brils
which are not acutely (over a period of 24^48 h)
toxic to islet cells.
Conversion of synthetic IAPP is accelerated both
in the presence of pre-formed ¢brils [37] or a ‘nu-
cleus’ [102]. In addition, IAPP ¢bril formation can
be stimulated by the presence of other amyloidogenic
peptides in ¢bril form [103]. This suggests that, in
vivo, once an extracellular ‘nidus’ is formed within
the islet space, IAPP monomers released during the
process of L-cell secretion could be converted rapidly
to L-conformation at the nucleation site and as-
sembled into ¢brils. The nature of the ‘nucleus’ or
‘nidus’ in diabetes is unclear but could consist of
insoluble aggregates (not necessarily in L-conforma-
tion) of proIAPP intermediates or IAPP fragments;
such fragments of IAPP have been identi¢ed in ex-
tracts of human pancreas and plasma [104]. Thus,
once a nucleation point had been established in the
islet, even small increases in L-cell activity as occurs
due to increased glucose concentrations in impaired
fasting glucose (IFG), in insulin resistant individuals
and in sulphonylurea therapy in diabetes, would pro-
mote ¢bril deposition. This has been demonstrated in
a feline experimental model of diabetes (a species in
which islet amyloid forms). Cats were made diabetic
by removal of part of the pancreas and insulin resis-
tance was increased by hormone treatment. At this
time no amyloid was formed but these animals were
then treated with either sulphonylurea to increase
L-cell secretion of insulin and IAPP or insulin to
reduce the requirement for endogenous secretion of
IAPP (and insulin) from L-cells [105]. Following this
treatment regime, islet amyloidosis was more exten-
sive in the sulphonylurea-treated animals than those
treated with insulin (Table 1): these data suggest that
prolonged stimulation of L-cells by sulphonylurea
therapy or sustained high glucose concentrations in
diabetes could lead to more extensive islet amyloid
formation and L-cell failure. This appears to be in
con£ict with the ¢ndings of the United Kingdom
Prospective Diabetes Study, UKPDS, where treat-
ment with diet, sulphonylurea or insulin was com-
pared in 5000 newly diagnosed patients [106]. There
was no apparent di¡erence in the rate of decline of
islet function from the time of diagnosis in patient
groups randomised to insulin or sulphonylurea treat-
ment. However, at present, there is little evidence
that islet amyloidosis is a major causative factor
for the onset and initial progression of the disease
in man. It would be of interest to compare, in these
well characterised patients, the extent of pancreatic
amyloid at post-mortem with the longitudinal pro-
gression of the disease.
5.2. Intracellular ¢bril formation
Fibril-like material has been described in L-cell
granules of hIAPP transgenic mice suggesting that
¢brils form before secretion of the peptide [107].
However, it remains to be con¢rmed if these very
small accumulations, which are visible only by elec-
tron microscopy, have the characteristic feature of
amyloid (congo red birefringence). Intracellular
IAPP ¢brils are found in unidenti¢ed organelles in
the cytoplasm in some human cells, notably human
insulinoma cells [108,109].
Such intracellular ¢brils, oriented in parallel ar-
rays, are frequently not enclosed by a visible mem-
brane (Fig. 6a) and are congo red positive and bi-
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Fig. 6. Intracellular amyloid ¢brils. (a) Fibrils in the cytoplasmic domain of a human insulinoma cell. There was no apparent membrane enclosing the bundle of ¢brils
which were largely in parallel orientation and immunoreactive for the N-terminus of proIAPP (10 nm gold) suggesting origin from the Golgi or ER organelles.
(b) Starburst-like orientation of intracellular ¢brils in an insulinoma cell. Fibrils were in close proximity to insulin granules and other cytoplasmic organelles. (c) Light
micrograph of specimen shown in panel b. When stained with congo red, the starburst ¢brils exhibited star-like green birefringence in polarised light (arrows). There
was no morphological evidence suggesting apoptosis in cells containing IAPP ¢brils. I, insulin granules. Scale bars: (a) 1 Wm; (b) 5 Wm; (c) 20 Wm.
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refringent in polarised light (Fig. 6b). Intracellular
¢brils have been reported in hIAPP transgenic mouse
islets [101], human transplanted islets [110] and in
massive amyloidosis associated with diabetes in hI-
APP transgenic mice treated with steroids [96]. Some
intracellular ¢brils show immunoreactivity for the
N-terminus of proIAPP (Fig. 6c) and have been
shown to be ubiquitinated [109]. These data suggest
that the component peptide of intracellular ¢brils is
proIAPP or an intermediate and that the ¢brils are
located in a pre-Golgi part of the secretory pathway,
possibly the endoplasmic reticulum (ER). Ubiquitin
targets misfolded intracellular proteins in the ER and
cytoplasm and directs them to the proteosomal deg-
radation pathway [111]. This could be a normal
pathway for disposal of misfolded IAPP intermedi-
ates before or after ¢brils are formed in the ER or
other cytoplasmic organelles.
Intracellular accumulation of hIAPP has been
noted in COS-1 cells transfected with the gene for
hIAPP [53,112]; DNA constructs were used to tran-
scribe either rat, human wild type IAPP or the S20G
mutant IAPP form. IAPP was shown to accumulate
in the ER and Golgi in these transfected cells and
cells expressing hIAPP showed a high degree of ap-
optosis. However, similar studies in other laborato-
ries with hIAPP cDNA transfected into COS-7 cells
[113] or AtT20 cells (C.E. Higham, personal commu-
nication) were unable to detect ¢brils. Accumulation
of transfected gene products in Golgi and ER sug-
gests that the peptide is not being transferred e⁄-
ciently through the constitutive secretory pathway
present in COS cells. This may be related to aggre-
gation of proIAPP in these organelles either in the
form of ¢brils or aggregates as COS cells do not
possess PC1 or PC2 required to process proIAPP
[68]. In a similar way, misfolded protein in the
form of insoluble aggregates accumulates in the ER
in human and rodent pituitary cells expressing mu-
tant vasopressin/oxytocin [114]. These types of intra-
cellular accumulations of misfolded/aggregated pro-
tein are likely to result in cellular dysfunction and
increased cell death even if ¢brils are not formed.
Intracellular accumulations of IAPP-immunoreactive
material (but not necessarily in the form of ¢brils)
have been identi¢ed in L-cell lysosomes of both dia-
betic and non-diabetic human subjects [115] and in
hIAPP transgenic mice [101]. Lysosomal IAPP accu-
mulations are derived from the process of crinophagy
whereby secretory granule components, including in-
sulin and IAPP are recycled within the cell via a
lysosomal degradation pathway [116,117]. Degrada-
tion of human IAPP by lysosomal enzymes appears
to be less e⁄cient than that for rodent IAPP or for
insulin. This high concentration of hIAPP in lyso-
somes is potentially a source for intracellular ¢bril
formation during cellular disintegration resulting
from apoptosis. Thus cell death in the islet, whatever
the cause, will result in release of hIAPP from intra-
cellular compartments, notably granules and lyso-
somes, and under appropriate conditions ¢brils,
could form.
Fibril formation from hIAPP is therefore possible
at more than one site and more than one aberrant
biochemical or physiological process can result in
IAPP ¢brillogenesis. Experimental modulation of
IAPP production in cellular systems in vitro or in
vivo will initiate one or more of these mechanisms.
More than one site of production of aberrantly
folded hIAPP has been demonstrated in a single cel-
lular system of hIAPP transgenic mouse islets cul-
tured under di¡erent conditions; IAPP was deposited
as extracelluar ¢brils but a small percentage of IAPP
accumulated as ¢brils at intracellular sites or in non-
¢brillar form outside the cells [100,101]. However,
the major site in the islet relevant for diabetes
in man is extracellular and adjacent to islet capilla-
ries.
6. Is islet amyloid responsible for L-cell destruction
and/or dysfunction in diabetes?
Synthetic human IAPP is acutely toxic to cultured
cells and islets in vitro [16,118,119]; the mechanism
of this cytotoxicity is mediated by apoptosis. These
e¡ects of synthetic peptide ¢brils has been attributed
to interaction of the ¢brillar form with cell mem-
branes to create pores and a¡ect normal transmem-
brane ionic currents [120]. Similar cytotoxic e¡ects
have been described for ¢brillar synthetic AL peptide
[18,121] but only when ¢brils are formed with ageing
since AL is not toxic when freshly prepared
[19,21,122]. It has been suggested that the toxic spe-
cies of the amyloidogenic peptides is not the mature
¢bril but an aberrantly folded form of the ¢bril pre-
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cursor, possibly a proto¢bril or small oligomer [123].
In the case of IAPP, this hypothesis was derived
partly from in vitro experiments demonstrating that
‘ageing’ of synthetic hIAPP preparations for days or
weeks decreased the degree of cytotoxicity [123].
However, these data have not been universally con-
¢rmed in all laboratories. Ageing of hIAPP under
di¡erent conditions did not a¡ect the degree of tox-
icity [18]; di¡erent preparations aged for more than
1 week inhibited similar degrees of cytotoxicity (Fig.
7). One explanation of these con£icting data is that
with time, synthetic IAPP ¢brils aggregate into larger
insoluble precipitates which are not equally dispersed
in the culture medium and, when added to the me-
dium will come in contact with less cells than if the
¢brils were dispersed. The nature of the toxic form of
hIAPP both in vitro and in vivo and the method of
induction of cell damage remains to be determined.
However, mechanisms operative in vitro may not
re£ect the events occurring in vivo in man where
the time scale for islet amyloid deposition and asso-
ciated cellular destruction could be much longer ^ in
the order of months or years ^ during the course of
the disease.
Biosynthetic IAPP ¢brils appear to be less toxic
than ¢brils formed from synthetic peptides since
¢brils formed in cultured transgenic islets do not
result in acute onset of cell death of adjacent cells
during the culture period [100,101]. However, the
margins of L-cells adjacent to extracellular IAPP
deposits show deep invaginations ¢lled with ¢brils
when IAPP is deposited in islets in vivo or in cellular
systems in vitro [4,40,109,124,125] (Fig. 8a,b).
Clathrin coated plasma membrane invaginations are
more frequently found adjacent to the ¢brils than in
the absence of ¢brils or other regions of the cell,
suggesting that recovery of membrane by endocytosis
is partly arrested by the presence of the ¢brils
(Fig. 8a). The interaction of extracellular ¢brils
with the adjacent L-cell membrane in amyloid
deposition could play an important role in decreasing
membrane £uidity resulting in interruption of trans-
membrane signalling. Thus a very small accumula-
tion of ¢brils adjacent to L-cells could modulate
glucose signalling via membrane GLUT2 transport-
ers and a¡ect potassium and calcium channels,
insulin granule exocytosis and membrane recovery.
If this hypothesis is correct, L-cell function could
be compromised with a small accumulation of
IAPP ¢brils without any substantial changes in
Fig. 7. Cytotoxicity of di¡erent preparations of human synthetic IAPP in vitro. The cytotoxic e¡ects of hIAPP were examined on
mouse islet LTC cells in culture and quanti¢ed by MTT reduction as a colorimetric test. Cell viability was expressed as a percentage
of MTT reduction in the wells containing medium plus rat IAPP (rIAPP) which was non-toxic. Conditions: 1, hIAPP diluted into cul-
ture medium from a 1 mg/ml stock solution in dH2O; 2, hIAPP reconstituted directly into medium from a freeze dried aliquot that
had previously been in 100% HFIP and ¢ltered (0.2 Wm) to ensure all ‘seeds’ were removed; 3, freeze dried aliquot as in 2, made up
at 1 mg/ml in dH2O and incubated for 1 week at 24‡C to ‘age the ¢brils’ before further dilution into culture medium; 4, freeze dried
aliquot as in 2, made up at 1 mg/ml in dH2O and incubated for 1 week at 37‡C to accelerate ‘ageing’ process. Electron microscopy
con¢rmed the presence of ¢brils in all hIAPP preparations. No di¡erences were seen in the toxic properties of these preparations.
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L-cell population arising as a result of ¢bril-induced
cell death.
7. Are laboratory and animal models accurate
representations of the amyloid deposition and
disease processes in diabetes?
The major problem in determination of the rela-
tionship between type 2 diabetes and islet amyloid-
osis is the di⁄culty in making observations in vivo in
man as pancreatic biopsies are ethically unaccept-
able. Animal models of spontaneously developing,
diabetes-associated islet amyloidosis are restricted
to older cats and monkeys kept in captivity
[38,39,41,93]. The monkey and feline models of dia-
betes have a similar diabetic syndrome to that seen in
man; the pathophysiology includes older age, obe-
sity, impaired glucose tolerance and ¢nally insulin
dependence. To address this research problem, at
least three di¡erent colonies of transgenic mice ex-
pressing the gene for human IAPP (hTM) have been
created [96,126^128] (Table 1). Animals in these col-
onies do not develop diabetes spontaneously and islet
amyloid deposition appears rarely even in very old
mice [128,129]. Amyloid deposition and diabetes
have been induced in these animals by creating a
background of obesity and increased insulin resis-
tance by various strategies including increased diet-
ary fat [130], treatment with steroids or hormones
[96,131] or by co-expression of obesity genes
[97,99]. However, it must be remembered that
although obesity is a risk factor for diabetes in
man this is not a complete model of human type 2
diabetes and progression of the syndromes is not
identical.
It is not possible to determine longitudinal pro-
gression of amyloidosis in man and the degree of islet
amyloidosis in diabetic patients is very variable at
post-mortem examination; the number of a¡ected
islets visible by light microscopy can be less than
1% or up to 80% in patients with long-established
diabetes (Fig. 9a,b). The distribution of islets a¡ected
by amyloid in the pancreas is not uniform [132] and
the degree of amyloidosis within an islet can be less
than 0.5% or more than 90% of the islet volume
[9,11]. These features indicate that islet amyloid is
variable and is not a major causative factor for onset
Fig. 8. Fibrils and morphology of the L-cell plasma membrane.
(a) Islet isolated from a hIAPP transgenic mouse and cultured
in vitro in 16.7 mM glucose. Fibrils (immunogold labelled for
IAPP, 10 nm gold) formed in the extracellular space close to
the margins of the cells. The plasma membrane was irregular
and some invaginations (arrows) have a thickened appearance
consistent with clathrin coating of an endocytotic ¢gure (arrow-
head). Interaction of ¢brils with the plasma membrane could
interrupt the £uidity of the lipid bilayer and a¡ect insulin gran-
ule release and membrane recapture and mobility of membrane
proteins such as GLUT2 glucose transporters. (b) Islet from a
human diabetic subject showing similar irregularity of the plas-
ma membrane adjacent to amyloid deposit with invaginations
into the L-cell. B, L-cell. (a,b) Scale bar = 200 nm.
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of diabetes in man. There is, however, a positive
relationship between more extensive islet amyloidosis
at post-mortem in man and more severe islet dys-
function as shown by the requirement for insulin
therapy [10,12,13]. In comparison, in most animal
models, there is progressively increasing islet amyloid
formation before the onset of hyperglycaemia [39,93]
and the degree of amyloidosis (numbers of islets af-
fected and size of amyloid deposits) appears to relate
to the onset of hyperglycaemia [39,97,99]. This im-
plicates islet amyloid (and the associated destruction
of islet cells) directly with development of hypergly-
caemia in these animal models (Fig. 10). In addition,
amyloid deposition in the relatively young hTM (less
than 1 year old) is more pronounced in males and is
increased by oophorectomy in females [130,133,134].
No such clear gender di¡erences in diabetes suscep-
tibility are seen in humans. The question of the iden-
tity of the relationship of islet amyloidosis to the
syndrome of diabetes in man and animal models re-
mains unanswered at present. It is likely that the
animal models are a better representation of the later
stages of the syndrome in man when islet dysfunction
is severe and L-cell mass is diminishing [135] (Fig.
10).
Development of amyloid in transgenic animal
models is thought to be promoted by increased pro-
duction of IAPP but that cannot be the only factor
since islet amyloid is not formed in hTM overex-
pressing IAPP unless against a background of obe-
sity (Table 1). Many studies in intact non-transgenic
animals and man have shown that IAPP and insulin
production change in a parallel fashion in response
to di¡erent L-cell stimulating agents and at di¡erent
stages of the diabetic syndrome; secretion of both
peptides is elevated in increased insulin resistance
and decreased with islet failure [136^139]. Although
it has been suggested that amyloid formation is ini-
tiated by speci¢c overproduction of IAPP, no con-
vincing evidence has been produced to demonstrate
disassociation of insulin and IAPP production at any
stage of diabetes (Table 1). Expression of the IAPP
transgene in hTM is under the control of the insulin
promoter and therefore is driven and controlled in
parallel with insulin by hyperglycaemia and tran-
scription factors. The IAPP and insulin gene pro-
moters have some degree of similarity but are not
identical [140^144]. In particular, cellular IAPP
Fig. 9. Di¡erent degrees of islet amyloidosis in two patients
with similar duration and clinical features of type 2 diabetes.
Amyloid was labelled with £uorescent thio£avin S in islets from
two diabetic subjects. (a) An islet from a subject (aged 84
years) who died after 12 years of type 2 diabetes treated with
sulphonylurea; quantitation demonstrated that 80% of islets
were a¡ected with amyloid and more than 85% islet area was
replaced with amyloid. (b) Subject aged 65 years, died after 10
years of diabetes treated with sulphonylurea; 6 1% islets con-
tained amyloid deposits and 6 1% islet area replaced with amy-
loid. Amyloid was present as thin perivascular deposits adjacent
to the capillary surrounding the islet and in larger accumula-
tions within the islet domain; margins of islets are indicated
with arrows. (a,b) Scale bar = 20 Wm.
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gene expression is increased whilst that of insulin is
reduced by dexamethasone [145]. Studies on human
isolated islets and L-cells have demonstrated that the
IAPP and insulin genes are not always co-ordinately
regulated in response to secretagogues and agents
that modulate L-cell gene expression
[72,141,146,147]. This would suggest that in non-
transgenic animals and man, di¡erent regulatory sys-
tems could control expression of these two L-cell
genes. To begin to answer the question of regulation,
it will be necessary to examine human IAPP expres-
sion and ¢bril formation in a model system where the
IAPP gene is regulated by its own promoter such as
in human islets or cells.
It has been assumed that islet amyloid deposition
in diabetes is an irreversible and progressively in-
creasing process. However, the absence of amyloid
in hIAPP transgenic mice could re£ect an e⁄cient
removal of ¢brils or nucleating aggregates rather
than a lack of ¢bril formation. It has been proposed
that amyloidosis is reversible and that there is con-
tinual turnover of ¢brils in deposits [86]. Systemic
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amyloid deposits have been shown to regress follow-
ing reduction of the source of the protein component
of the ¢brils [148]. However, islet amyloid deposits
are most extensive in patients and hTM where few
L-cells remain to continue to provide IAPP for ¢bril
formation. Since IAPP ¢brils are insoluble in aque-
ous medium, islet amyloidosis has all the hallmarks
of a progressive and irreversible disease process.
8. Conclusions
In spite of the increased information from trans-
genic mouse and cellular models, the process of amy-
loid deposition and its relationship to diabetes re-
main an enigma. It appears that there are speci¢c
factors/processes associated with human diabetes
(which are also ongoing in insulinomas) which cause
changes in the molecular conformation of mono-
meric IAPP resulting in accumulation and formation
of ¢brils. These aberrant processes occur in normal
physiological conditions in vivo and have little in
common with the extreme denaturing biochemical
conditions required to convert intrinsically non-
amyloidogenic proteins into L-sheet [149]. It is likely
that L-cell dysfunction in diabetes creates an environ-
ment which promotes or permits misfolding of IAPP.
Research over the past 13 years, since the identi¢ca-
tion of IAPP, has increased our understanding of the
biophysics of IAPP folding and the process of amy-
loid deposition in islets. However, more questions
still remain to be answered:
b What are the primary factors for L-cell dysfunction
in diabetes?
b Are they genetically determined and associated
with IAPP?
b How do these factors a¡ect production, folding
and misfolding of IAPP?
b How does amyloid deposition a¡ect L-cell function
in diabetes?
Islet amyloid and hyperglycaemia are present in
more than 90% of patients. Type 2 diabetes has
very heterogeneous clinical and pathophysiological
features. If amyloid contributes to the ¢nal stages
of the syndrome when insulin therapy is required,
it is important that strategies be developed to iden-
tify patients at risk and to devise therapies which
reduce ¢bril deposition and the ¢nal demise of the
L-cell. Over the past decade, the increased interest in
protein/peptide folding and amyloid structure has
Fig. 10. Hypothetical model indicating potential pathways linking IAPP ¢bril formation with diabetes in animal models and man. In
man, genetic factors, susceptibility genes, coupled with adverse environmental conditions (inactivity and high fat diet) lead to changes
in function of insulin-secreting L-cells. No phase of inappropriate overexpression of IAPP has been identi¢ed in diabetes, although the
IAPP and insulin gene promoters are not identical. Abnormal proteolytic processing of proIAPP (and proinsulin) in susceptible indi-
viduals results in accumulation of misprocessed proIAPP either in the cell (which will form ¢brils under some conditions or be cleared
via the ubiquitin pathway) or in the extracellular space. Interaction with basement membrane components (HSPG) will delay transfer
to the circulation and generate a ‘nidus’ or ‘seed’ in the islet. The onset of obesity-linked increased insulin resistance and hyperglycae-
mia of type 2 diabetes will further modulate L-cell function although there is no evidence for disproportionate increased IAPP secre-
tion. This will result initially in an increase in L-cell secretion/decreased clearance and exacerbate the accumulation of proIAPP/IAPP
in the islet. Increased concentration of hydrophobic hIAPP in the accumulations will create the environment that promotes molecular
rearrangement of the peptide and misfolding to form L-sheets, then proto¢brils, proto¢laments and ¢nally ¢brils. Interaction of the
oligomers, proto¢laments or ¢brils with the L-cell plasma membrane will further compromise L-cell function. However, severe deterio-
ration of L-cell dysfunction (and requirement for insulin therapy) will result only from extensive accumulation of amyloid and associ-
ated loss of L-cells by ¢bril-induced toxicity. In animal models, islet amyloidosis is arti¢cially/experimentally created either by in-
creased consumption of food (animals in captivity or domestic environment) or by genetic manoeuvres (transgenic mice TM
expressing the hIAPP gene regulated by an insulin promoter, genetic background of obesity) or environment or drugs (high fat diet,
steroids). These factors which promote L-cell secretion could increase the production of misprocessed proIAPP but this has yet to be
demonstrated. ProIAPP/IAPP production is increased by more than 20 times in most transgenic mouse models but additional factors
are required to generate amyloid. In most animal models, islet amyloid is present before the onset of hyperglycaemia and the degree
of amyloidosis (and/or the associated loss of L-cells) appear to determine the onset and severity of hyperglycaemia.
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changed the focus from the putative physiology and
function of ‘amylin’, IAPP, to the process of misfold-
ing in diabetes. A century of scienti¢c development
has transformed Opie’s landmark observations [1]
from hand drawn pictures of a microscope ¢eld to
computer modelling of complex molecular processes.
Will advances in proteomics during the next century
solve the molecular puzzle of protein folding and the
biochemistry of diabetes and allow development of
appropriate therapies?
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